Expansion of PD1-positive T Cells in Nodal Marginal Zone Lymphoma: A Potential Diagnostic Pitfall.


Journal

The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904

Informations de publication

Date de publication:
05 2020
Historique:
pubmed: 26 11 2019
medline: 29 7 2020
entrez: 26 11 2019
Statut: ppublish

Résumé

The diagnosis of nodal marginal zone lymphoma (NMZL) can be challenging, with the differential diagnosis including other low-grade B-cell lymphomas, reactive hyperplasia, and even some cases of peripheral T-cell lymphoma (PTCL). PTCL may have a perifollicular growth pattern mimicking NMZL. We and others have noted an atypical distribution of T-follicular helper (TFH) cells in some cases of NMZL. This study was prompted by the diagnosis of NMZL in several cases in which a marked increase of TFH cells, as determined by staining for programmed death-1 (PD1), had prompted suspicion for a diagnosis of PTCL. We analyzed PD1 staining in 48 cases of NMZL to characterize the extent and pattern of the PD1-positive infiltrate. Three main patterns of PD1 staining were identified: follicular pattern (peripheral, n=16; central, n=9; mixed, n=3), diffuse pattern (n=4), and a reduced or normal staining pattern in residual follicles (n=16). A comprehensive analysis of other TFH markers was undertaken in 14 cases with a high content of PD1-positive cells that were confirmed as B-cell lymphoma by clonality analysis. We describe in detail 5 of these cases in which PTCL was an initial consideration. This study illuminates the diverse immunohistochemical patterns encountered in NMZL and highlights a diagnostic pitfall important for diagnostic accuracy.

Identifiants

pubmed: 31764221
doi: 10.1097/PAS.0000000000001414
pii: 00000478-202005000-00010
pmc: PMC8189156
mid: NIHMS1699204
doi:

Substances chimiques

Biomarkers, Tumor 0
PDCD1 protein, human 0
Programmed Cell Death 1 Receptor 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

657-664

Subventions

Organisme : Intramural NIH HHS
ID : Z01 SC000550
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

J Mol Diagn. 2003 May;5(2):82-7
pubmed: 12707372
Histopathology. 2019 Aug;75(2):287-290
pubmed: 30860612
Leukemia. 2003 Dec;17(12):2257-317
pubmed: 14671650
Haematologica. 2013 Jul;98(7):1003-13
pubmed: 23813646
Virchows Arch. 2006 Jul;449(1):78-87
pubmed: 16633785
Pathol Int. 2002 May-Jun;52(5-6):400-5
pubmed: 12100523
Am J Surg Pathol. 2001 Mar;25(3):395-400
pubmed: 11224611
J Clin Pathol. 1992 Sep;45(9):770-5
pubmed: 1401205
Am J Surg Pathol. 2007 Sep;31(9):1310-22
pubmed: 17721185
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
Mod Pathol. 2009 Jun;22(6):753-61
pubmed: 19329936
Histopathology. 2013 Oct;63(4):482-98
pubmed: 23855758
Am J Surg Pathol. 1999 Jan;23(1):59-68
pubmed: 9888704
Pathobiology. 2010;77(1):24-7
pubmed: 20185964
Am J Surg Pathol. 2010 Feb;34(2):178-89
pubmed: 20087161
Am J Surg Pathol. 2000 Jan;24(1):117-22
pubmed: 10632495
Am J Surg Pathol. 2010 Oct;34(10):1425-35
pubmed: 20871216
Am J Surg Pathol. 2006 Jul;30(7):802-10
pubmed: 16819321
Hum Pathol. 1994 Dec;25(12):1269-75
pubmed: 8001920
Mod Pathol. 2002 Apr;15(4):420-5
pubmed: 11950916
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Am J Surg Pathol. 2007 Jul;31(7):1077-88
pubmed: 17592275
J Clin Oncol. 2013 Jan 10;31(2):e28-30
pubmed: 23213091

Auteurs

Caoimhe Egan (C)

National Institutes of Health, Bethesda, MD.

Camille Laurent (C)

Toulouse Center of Research on Cancer-Oncopole, CHU Toulouse, CRCT Inserm U1037, Toulouse, France.

Julie C Alejo (JC)

National Institutes of Health, Bethesda, MD.

Stefano Pileri (S)

European Institute of Oncology, IRCCS-Scientific Institute for Research, Hospitalization and Health Care, Milan, Italy.

Elias Campo (E)

Hospital Clinic of Barcelona, University of Barcelona, Barcelona.

Steven H Swerdlow (SH)

Department of Pathology, University of Pittsburgh, Pittsburgh, PA.

Miguel Piris (M)

Jiménez Díaz Foundation University Hospital, Madrid, Spain.

Wing C Chan (WC)

City of Hope Medical Center, Duarte.

Roger Warnke (R)

Department of Pathology, Stanford University, Stanford, CA.

Randy D Gascoyne (RD)

British Columbia Cancer, Centre for Lymphoid Cancer, Vancouver, BC, Canada.

Liqiang Xi (L)

National Institutes of Health, Bethesda, MD.

Mark Raffeld (M)

National Institutes of Health, Bethesda, MD.

Stefania Pittaluga (S)

National Institutes of Health, Bethesda, MD.

Elaine S Jaffe (ES)

National Institutes of Health, Bethesda, MD.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH